Altimmune (ALT) Expected to Announce Earnings on Thursday

Altimmune (NASDAQ:ALT) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect Altimmune to post earnings of ($0.36) per share and revenue of $0.00 million for the quarter.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. On average, analysts expect Altimmune to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Altimmune Price Performance

Shares of ALT stock opened at $5.43 on Tuesday. The stock’s 50-day moving average is $5.15 and its 200 day moving average is $6.64. Altimmune has a 1-year low of $3.55 and a 1-year high of $11.16. The company has a market cap of $418.19 million, a P/E ratio of -3.50 and a beta of 1.13.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ALT shares. William Blair reaffirmed a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Thursday, April 3rd. Finally, Stifel Nicolaus began coverage on Altimmune in a research report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price objective for the company. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $20.83.

Insider Activity

In other Altimmune news, CFO Gregory L. Weaver purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were bought at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares in the company, valued at $52,000. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 4.10% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.